2018
Animal models of cholangiocarcinoma: What they teach us about the human disease
Cadamuro M, Brivio S, Stecca T, Kaffe E, Mariotti V, Milani C, Fiorotto R, Spirli C, Strazzabosco M, Fabris L. Animal models of cholangiocarcinoma: What they teach us about the human disease. Clinics And Research In Hepatology And Gastroenterology 2018, 42: 403-415. PMID: 29753731, DOI: 10.1016/j.clinre.2018.04.008.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAnimal modelsNovel therapeutic approachesRelevant animal modelsPathogenesis of cholangiocarcinomaBiliary carcinogenesisTreatment optionsTherapeutic approachesRodent modelsLethal cancersClinical phenotypeExperimental modelCholangiocarcinomaAggressive behaviorCell interactionsHuman diseasesComplex cell biologyMultiple cell interactionsMolecular perturbationsPathogenesisTumorsCancerDiseaseCarcinogenesis
2014
Management of treatment‐naïve chronic hepatitis C genotype 1 patients: a cost‐effectiveness analysis of treatment options
Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, Vinci M, Belli LS, Mantovani LG, Strazzabosco M. Management of treatment‐naïve chronic hepatitis C genotype 1 patients: a cost‐effectiveness analysis of treatment options. Journal Of Viral Hepatitis 2014, 22: 175-183. PMID: 25040391, PMCID: PMC4519006, DOI: 10.1111/jvh.12278.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioEnd-stage liver diseaseCost-effectiveness analysisF3-F4Liver diseaseChronic hepatitis C genotype 1 patientsHepatitis C genotype 1 patientsItalian National Health System perspectiveNational Health System perspectiveResponse-guided therapyGenotype 1 patientsMETAVIR fibrosis stageHealth system perspectiveQuality-adjusted life yearsPatient selection strategiesCost-effectiveness ratioG1 patientsNaive patientsTriple therapyOnly patientsAdvanced fibrosisFuture regimensMore regimensTreatment optionsFibrosis stage